Blueprint Medicines (BPMC) News Today $128.20 +0.08 (+0.06%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$128.18 -0.01 (-0.01%) As of 06/20/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPMC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint ...June 22 at 1:56 PM | morningstar.comSG Americas Securities LLC Has $644,000 Position in Blueprint Medicines Corporation (NASDAQ:BPMC)SG Americas Securities LLC boosted its position in Blueprint Medicines Corporation (NASDAQ:BPMC - Free Report) by 70.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,276 shares of the biotechnology company's stock after pJune 22 at 3:13 AM | marketbeat.comBLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMCJune 20 at 4:36 PM | businesswire.comWells Fargo & Company Downgrades Blueprint Medicines (NASDAQ:BPMC) to HoldJune 19, 2025 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Earns Equal Weight Rating from Wells Fargo & CompanyWells Fargo & Company reaffirmed an "equal weight" rating and issued a $129.00 target price (down previously from $143.00) on shares of Blueprint Medicines in a research report on Tuesday.June 17, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Sees Large Volume Increase - Should You Buy?Blueprint Medicines (NASDAQ:BPMC) Sees Large Volume Increase - What's Next?June 16, 2025 | marketbeat.comHAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC)June 15, 2025 | globenewswire.comAssenagon Asset Management S.A. Reduces Position in Blueprint Medicines Co. (NASDAQ:BPMC)Assenagon Asset Management S.A. trimmed its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 21.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 76,270 shares of the biotechnology company's stock afterJune 15, 2025 | marketbeat.comGAMMA Investing LLC Purchases 28,615 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)GAMMA Investing LLC boosted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 11,972.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,854 shares of the biotechnology company's stock after aJune 13, 2025 | marketbeat.comBlueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesJune 12, 2025 | prnewswire.comBlueprint Medicines (NASDAQ:BPMC) Reaches New 12-Month High - Should You Buy?Blueprint Medicines (NASDAQ:BPMC) Reaches New 52-Week High - What's Next?June 11, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Stake Raised by Rhumbline AdvisersRhumbline Advisers grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 91,933 shares of the biotechnology company'June 11, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Sees Strong Trading Volume - Here's WhyBlueprint Medicines (NASDAQ:BPMC) Sees Strong Trading Volume - Should You Buy?June 10, 2025 | marketbeat.comBest Growth Stocks To Follow Now - June 9thBlueprint Medicines, Novo Nordisk A/S, Welltower, SpringWorks Therapeutics, Blackstone, BlackRock, and Boston Properties are the seven Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to deliver above-average revenue and earJune 9, 2025 | marketbeat.comUBS Sticks to Its Hold Rating for Blueprint Medicines (BPMC)June 8, 2025 | theglobeandmail.comNBC Securities Inc. Purchases 2,646 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)NBC Securities Inc. lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 132,300.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,648 shares of the biotechnoloJune 8, 2025 | marketbeat.comGrowth Stocks To Follow Now - June 5thBlueprint Medicines, Novo Nordisk A/S, BlackRock, Blackstone, and Welltower are the five Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies whose revenues and earnings are expected to grow at an above-average rate relative to the overaJune 5, 2025 | marketbeat.comMorgan Stanley Issues Positive Forecast for Blueprint Medicines (NASDAQ:BPMC) Stock PriceMorgan Stanley upped their price objective on Blueprint Medicines from $102.00 to $129.00 and gave the company an "equal weight" rating in a report on Thursday.June 5, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Given New $129.00 Price Target at UBS GroupUBS Group increased their price target on Blueprint Medicines from $88.00 to $129.00 and gave the company a "neutral" rating in a research report on Thursday.June 5, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by GuggenheimGuggenheim downgraded shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a report on Tuesday.June 5, 2025 | marketbeat.comCiti Sticks to Its Sell Rating for Blueprint Medicines (BPMC)June 4, 2025 | theglobeandmail.comCitigroup Upgrades Blueprint Medicines (BPMC)June 4, 2025 | msn.comPromising Mid Cap Stocks To Follow Now - June 3rdBlueprint Medicines, Direxion Daily TSLA Bull 2X Shares, Oklo, Applied Digital, and D-Wave Quantum are the five Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of publicly traded companies whose market capitalization generally falls between abJune 4, 2025 | marketbeat.comTop Pharmaceutical Stocks To Watch Now - June 3rdBlueprint Medicines, Eli Lilly and Company, D-Wave Quantum, Merck & Co., Inc., Thermo Fisher Scientific, Regeneron Pharmaceuticals, and Pfizer are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded compaJune 4, 2025 | marketbeat.comPromising Growth Stocks To Follow Now - June 3rdBlueprint Medicines, Novo Nordisk A/S, and Incyte are the three Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares in companies whose earnings and revenues are expected to grow at an above-average rate compared to the broader market. These companieJune 4, 2025 | marketbeat.comTop Growth Stocks To Follow Now - June 4thBlueprint Medicines, Novo Nordisk A/S, BlackRock, Venture Global, SpringWorks Therapeutics, Blackstone, and Welltower are the seven Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to increase their earnings and revenues atJune 4, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Sees Large Volume Increase - What's Next?Blueprint Medicines (NASDAQ:BPMC) Sees Strong Trading Volume - Should You Buy?June 4, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Upgraded by Citigroup to "Neutral" RatingCitigroup raised Blueprint Medicines from a "sell" rating to a "neutral" rating and increased their price target for the stock from $83.00 to $129.00 in a research report on Wednesday.June 4, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Cut to "Hold" at TD CowenTD Cowen cut shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a research report on Tuesday.June 4, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by Citizens JmpCitizens Jmp cut shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a research report on Tuesday.June 4, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of "Hold" by AnalystsBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) has been given an average rating of "Hold" by the eighteen brokerages that are covering the stock, Marketbeat.com reports. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy ratJune 4, 2025 | marketbeat.comPromising Value Stocks To Follow Today - June 2ndBlueprint Medicines, CoreWeave, Inc. Class A Common Stock, Applied Digital, ProShares UltraPro Short QQQ, and Tempus AI are the five Value stocks to watch today, according to MarketBeat's stock screener tool. Value stocks are shares of companies that appear undervalued by the market relative to theJune 3, 2025 | marketbeat.comMid Cap Stocks To Keep An Eye On - June 2ndBlueprint Medicines, Applied Digital, and Direxion Daily TSLA Bull 2X Shares are the three Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of publicly traded companies whose total market capitalization generally falls between about $2 billionJune 3, 2025 | marketbeat.comPharmaceutical Stocks To Consider - June 2ndBlueprint Medicines, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals, Gilead Sciences, D-Wave Quantum, and Johnson & Johnson are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are equity shares of companies thaJune 3, 2025 | marketbeat.comTop Medical Stocks To Research - June 2ndBlueprint Medicines, UnitedHealth Group, and Tempus AI are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies operating in the healthcare sector—this includes pharmaceutical manufacturers, biotechnology firmJune 3, 2025 | marketbeat.comPromising Growth Stocks To Follow Today - June 2ndBlueprint Medicines, Novo Nordisk A/S, and Basel Medical Group are the three Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to grow their revenues and earnings at above-average rates, often reinvesting profits into expansiJune 3, 2025 | marketbeat.comBlueprint Medicines' (BPMC) Sector Perform Rating Reiterated at ScotiabankScotiabank reissued a "sector perform" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a report on Monday.June 3, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Earns "Neutral" Rating from JPMorgan Chase & Co.JPMorgan Chase & Co. reissued a "neutral" rating and issued a $129.00 target price (down from $130.00) on shares of Blueprint Medicines in a report on Monday.June 3, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Shares Gap Up - Still a Buy?Blueprint Medicines (NASDAQ:BPMC) Shares Gap Up - Should You Buy?June 3, 2025 | marketbeat.comWedbush Downgrades Blueprint Medicines (BPMC)June 3, 2025 | msn.comSanofi to buy Blueprint Medicines for $9.1BJune 3, 2025 | msn.comBlueprint Medicines (NASDAQ:BPMC) Given "Market Perform" Rating at JMP SecuritiesJMP Securities reissued a "market perform" rating on shares of Blueprint Medicines in a research report on Tuesday.June 3, 2025 | marketbeat.comStephens Reiterates "Equal Weight" Rating for Blueprint Medicines (NASDAQ:BPMC)Stephens reaffirmed an "equal weight" rating and set a $135.00 price target (down from $150.00) on shares of Blueprint Medicines in a report on Tuesday.June 3, 2025 | marketbeat.comWolfe Research Reaffirms Peer Perform Rating for Blueprint Medicines (NASDAQ:BPMC)Wolfe Research reaffirmed a "peer perform" rating on shares of Blueprint Medicines in a research note on Tuesday.June 3, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Reaches New 1-Year High - Here's WhyBlueprint Medicines (NASDAQ:BPMC) Sets New 52-Week High - Here's WhyJune 3, 2025 | marketbeat.comJP Morgan Downgrades Blueprint Medicines (BPMC)June 3, 2025 | msn.comWhy Blueprint Medicines Corporation (BPMC) Skyrocketed On MondayJune 3, 2025 | msn.comCalifornia State Teachers Retirement System Increases Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)California State Teachers Retirement System lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 4.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,259 shares of the biotechnology company'sJune 3, 2025 | marketbeat.comSanofi to buy US biopharma group Blueprint for up to $9.5 billionJune 3, 2025 | msn.comSanofi finds M&A fix for its multiple itchesJune 2, 2025 | reuters.com Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Media Mentions By Week BPMC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMC News Sentiment▼0.520.67▲Average Medical News Sentiment BPMC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMC Articles This Week▼79▲BPMC Articles Average Week Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ONC News Today BNTX News Today TEVA News Today SMMT News Today GMAB News Today ITCI News Today RDY News Today ASND News Today VTRS News Today QGEN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BPMC) was last updated on 6/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
